Predictive value of topoisomerase Ioc and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
1998

Predictive Value of Topoisomerase IIa and Other Factors in Breast Cancer Chemotherapy

Sample size: 55 publication Evidence: moderate

Author Information

Author(s): TAH Jarvinen, K Holi, T Kuukasjarvi, JJ Isola

Primary Institution: Tampere University Hospital

Hypothesis

Can topoisomerase IIa expression and other biomarkers predict the response to epirubicin chemotherapy in advanced breast cancer?

Conclusion

Topoisomerase IIa expression does not predict response to epirubicin chemotherapy, while c-erbB2 overexpression and negative estrogen receptor status are associated with poor response.

Supporting Evidence

  • Topoisomerase IIa expression did not correlate with treatment response.
  • c-erbB2 overexpression was significantly associated with poor response to chemotherapy.
  • Negative estrogen receptor status predicted lower response rates.

Takeaway

Doctors wanted to see if a certain protein could help predict how well breast cancer patients would respond to a specific treatment, but it turns out it doesn't help at all.

Methodology

The study analyzed the expression of topoisomerase IIa and other biomarkers in tumor samples from 55 patients treated with epirubicin, assessing their response to treatment.

Limitations

The study only included patients treated with a single-agent chemotherapy and did not account for other potential confounding factors.

Participant Demographics

Patients with advanced breast cancer, including node-negative and node-positive cases.

Statistical Information

P-Value

0.0021

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication